Skip to main content
AmigoFish

Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab

From Oncology Brothers: Practice-Changing Cancer Discussions · · 21 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.

Join us as we discussed:

- The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma

- The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions

- Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind

- The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes

We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- ⁠X/Twitter: https://x.com/oncbrothers

- ⁠Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes!

#HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem